We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Our Focus on Ophthalmology

It’s hard to comprehend vision loss in a world made for people who can see – but it’s clear to us. The daily burden. The challenges to independence. The impact on loved ones.

That’s why we’re relentless in our mission to save sight. Guided by patient needs, we’re driven to develop innovative treatments that will help fight vision loss and define vision care for decades.

We live for the day when patients can see us as clearly as we see them.

Our Commitment

Our commitment to advancing vision care is about far more than fighting vision loss. It’s about enhancing every aspect of the patient experience, ensuring equitable access to our treatments for all who need them and improving the lives of people with vision-threatening conditions.

True innovation for these patients demands scientific curiosity fueled by passion and rigor. We’re following the science to build an unrivaled ophthalmology pipeline of life-changing treatments that patients need next.

Read personal stories from people living with retinal conditions here:

Advancing Diversity & Inclusion in Ophthalmology

Serving diverse patient populations starts with inclusive, representative research. We launched the first company-sponsored retinal study of its kind to examine diabetic macular edema (DME) in underrepresented populations – specifically among Black, African American, Hispanic, Latin American, and Indigenous people. We are also conducting additional exploratory ophthalmology research and analyses with a diversity and inclusion focus. Beyond clinical studies, we are advancing diversity and inclusion in ophthalmology by supporting young scientists from underrepresented backgrounds.

Learn more about our long-term efforts to provide equitable care for all people in need.

Our Pipeline

We invest continually and for the long term – advancing the research, development and expertise needed to improve patients’ lives. Our robust clinical development program is evaluating potential treatments for vision-threatening eye conditions including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), retinal vein occlusion (RVO), geographic atrophy (GA) and more.

We are also applying the power of personalized healthcare through the integration of data, analytics, and technology to continuously individualize and improve the full care experience.

LEARN MORE ABOUT OUR OPHTHALMOLOGY PIPELINE

Our Heritage

Our history of scientific discovery is foundational to our progress in ophthalmology. And since the beginning, our work has been rooted in the needs of patients, who have always driven our unwavering efforts to develop sight-saving therapies. At the same time, we continue to seek new platforms, pathways and technologies in the ongoing fight against vision loss.

Our Perspectives

Learn more about the field, our research, and the people behind the science.

Our News & Publications

Read the latest news and publications about our work in ophthalmology.

The Lancet, January 2022
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
The Lancet, January 2022
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
Translational Vision Science & Technology, May 2021
Feasibility Study of a Multimodal, Cloud-Based, Diabetic Retinal Screening Program in a Workplace Environment
Retina, January 2021
The Angiopoietin/Tie Pathway In Retinal Vascular Diseases: A Review
Ophthalmology Retina, November 2020
End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
Translational Vision Science & Technology, September 2020
Development of Deep Learning Models to Predict Best-Corrected Visual Acuity from Optical Coherence